Old drug, new hope: could filgotinib tame rare immune diseases?
NCT ID NCT06285539
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term steroids. Sixty adults with active disease will receive the drug and be monitored for changes in symptoms and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Filgotinib (a JAK inhibitor drug)
What this could lead to
If successful, this could offer a new, more targeted treatment option for three rare inflammatory diseases, potentially reducing reliance on high-dose steroids.
What could go wrong
This is a small, early-phase trial (60 participants) testing a drug already approved for other conditions. It may not show enough benefit or could have side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, Netherlands
Contact Email: •••••@•••••
Contact
Contact
-
Erasmus MC
RECRUITINGRotterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Hagaziekenhuis
RECRUITINGThe Hague, Netherlands
Contact Email: •••••@•••••
Contact
-
Radboud university medical center
RECRUITINGNijmegen, Netherlands
Contact Email: •••••@•••••
Contact
-
University Medical Center
RECRUITINGUtrecht, Netherlands
Contact Email: •••••@•••••
Contact
Contact
-
Zuyderland Medical Center
RECRUITINGHeerlen, Netherlands
Contact Email: •••••@•••••
Contact